Edition:
India

ANI Pharmaceuticals Inc (ANIP.OQ)

ANIP.OQ on NASDAQ Stock Exchange Global Market

29.39USD
8:38pm IST
Change (% chg)

$-1.24 (-4.05%)
Prev Close
$30.63
Open
$30.83
Day's High
$30.83
Day's Low
$29.39
Volume
5,856
Avg. Vol
49,641
52-wk High
$86.67
52-wk Low
$29.38

Select another date:

Mon, Jul 6 2020

BRIEF-ANI Pharmaceuticals Announces Acquisition Of Fluconazole Tablets

* ANI PHARMACEUTICALS ANNOUNCES ACQUISITION OF FLUCONAZOLE TABLETS

BRIEF-ANI Pharmaceuticals Announces Launch Of Mexiletine Hydrochloride Capsules

* ANI PHARMACEUTICALS ANNOUNCES LAUNCH OF MEXILETINE HYDROCHLORIDE CAPSULES

BRIEF-ANI Pharmaceuticals Says Making Progress To Address Items Identified In FDA's Refusal To File Letter Relating To Cortrophin Gel sNDA Filing

* ANI PHARMACEUTICALS - CONTINUES TO MAKE PROGRESS TO ADDRESS ITEMS IDENTIFIED IN FDA'S REFUSAL TO FILE LETTER RELATING TO CORTROPHIN GEL SNDA FILING

BRIEF-ANI Pharmaceuticals Says Got Confirmation From Nasdaq Company Is No Longer In Compliance With Some Requirements

* ANI PHARMACEUTICALS - ON MAY 11, CO GOT CONFIRMATION FROM NASDAQ CO IS NO LONGER IN COMPLIANCE WITH NASDAQ'S AUDIT COMMITTEE COMPOSITION REQUIREMENTS

BRIEF-ANI Pharmaceuticals Reports Q1 2020 Results And Appoints Interim CEO

* ANI PHARMACEUTICALS REPORTS FIRST QUARTER 2020 RESULTS AND APPOINTS INTERIM CEO

BRIEF-Ani Receives Refusal To File Letter From FDA For Cortrophin® Gel

* ANI RECEIVES REFUSAL TO FILE LETTER FROM FDA FOR CORTROPHIN® GEL

BRIEF-Ani Announces Upcoming Departure Of CEO

* ANI PHARMACEUTICALS - ARTHUR S. PRZYBYL WILL DEPART AS PRESIDENT AND CHIEF EXECUTIVE OFFICER ON MAY 10, 2020

BRIEF-Ani Says FDA Accepts Supplemental Filing For Cortrophin® Gel

* ANI ANNOUNCES FDA ACCEPTANCE OF SUPPLEMENTAL FILING FOR CORTROPHIN® GEL 80 U/ML

BRIEF-ANI Pharmaceuticals Announces The Filing Of A Prior Approval Supplement For Purified Cortrophin Gel

* ANI PHARMACEUTICALS ANNOUNCES THE FILING OF A PRIOR APPROVAL SUPPLEMENT FOR PURIFIED CORTROPHIN® GEL 80 U/ML Source text for Eikon: Further company coverage:

BRIEF-ANI Pharma Announces FDA Approval Of Memantine Hydrochloride Extended-Release Capsules

* ANI PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF MEMANTINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULES

Select another date: